Login
PROTHENA CORP PUBLIC LTD CO logo

PROTHENA CORP PUBLIC LTD CO

prothena.com

What Do They Do?

Develops investigational therapies that target misfolded proteins for neurodegenerative and rare amyloid diseases, working with pharmaceutical companies on clinical development and licensing.

How Do They Make Money?

Pharmaceutical partners pay upfront and option fees, for research and manufacturing services, and milestone payments when programs reach clinical, regulatory or sales targets; agreements may also bring royalties. Prothena also receives payment for intellectual property and related rights.

revenue
SegmentShareRevenue
Collaboration revenue
99%
FY2022: 26%
Revenue from license and intellectual property
Licensed
0.5%
FY2022: 74%

Who Are Their Customers?

Drug-company partners work with Prothena through licensing and collaboration agreements, including Roche and Bristol Myers Squibb; Novo Nordisk acquired its ATTR amyloidosis business.

Do Revenues Turn Into Profits?

No. It lost $244.1M in FY2025.

Operating income, FY2025
−2216% of revenue
▼ −39% (Loss) vs FY2024 (−$154.6M, −114%)
Net income, FY2025
−2521% of revenue
▼ −100% (Loss) vs FY2024 (−$122.3M, −90%)
Free cash flow, FY2025
−1691% of revenue
▼ −9% (Loss) vs FY2024 (−$150.3M, −111%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −74%
vs $2.4M in Q3 FY2025
Net income
▲ +55% (Loss)
vs −$36.5M in Q3 FY2025
Collaboration revenue share of revenue vs 100.0% in Q3 FY2025

Shrinking. Revenue fell 95% in 4 years, from $200.6M in FY2021 to $9.7M in FY2025, about 53% a year.

Clinical portfolio The older report included company-owned clinical programs in AL amyloidosis and Alzheimer’s; the latest describes its active clinical portfolio as partnered, with wholly owned work focused on research and preclinical development.

Revenue over time
Collaboration revenue Revenue from license and intellectual property
$250M$125M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support